Fluticasone /Formoterol /Glycopyrronium
Phase 3Small molecule
Fluticasone /Formoterol /Glycopyrronium is one of 28 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
557 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1Veramyst
GSKPreclinical
Flovent
GSKPreclinical
Spiriva
Boehringer IngelheimPreclinical
Fluticasone /Formoterol /Glycopyrronium
EEurofarma Laboratorios S.A.
Phase 3
Aclidinium Bromide
AstraZenecaPreclinical
Duragesic
CCephalon
Preclinical
Coumadin
AAbbott
Preclinical
Narcan
SScienture
Preclinical
Zoloft
VViatris Specialty LLC
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- EEurofarma Laboratorios S.A.